Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia

The treatment of chronic myeloid leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKIs), such as imatinib, has yielded clinical success. However, the direct targeting of BCR-ABL does not eradicate CML cells expressing mutant BCR-ABL, especially the T315I mutation in BCR-ABL. Moreover, increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Ke, Wang, Fang, Zhang, Hong, Wang, Xiaokun, Chen, Likun, Su, Xiaodong, Wu, Xingping, Han, Qianqian, Chen, Zhen, Chen, Zhe-Sheng, Fu, Liwu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873979/
https://www.ncbi.nlm.nih.gov/pubmed/33585207
http://dx.doi.org/10.3389/fonc.2020.588641

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873979/
https://www.ncbi.nlm.nih.gov/pubmed/33585207
http://dx.doi.org/10.3389/fonc.2020.588641

Ejemplares similares